Progress
Your baseline and follow-up results
Every priority marker and physical measure is shown beside its baseline, with the change and direction of travel.
Lab markers improved
51/53
Physical measures improved
23/23
Biological age
−11.6 yrs
Endocrine - full axis
Testosterone axis
| Marker | Baseline | Follow-up | Change | Trend | Status |
|---|---|---|---|---|---|
| Total testosteroneng/dL | 412 | 782 | +90% | Optimal | |
| Free testosteronepg/mL | 61 | 168 | +175% | Optimal | |
| Bioavailable testosteroneng/dL | 148 | 361 | +144% | Optimal | |
| SHBGnmol/L | 52 | 33 | −37% | Optimal | |
| Albuming/dL | 4.1 | 4.6 | +12% | Optimal | |
| Free androgen indexratio | 27 | 82 | +204% | Optimal | |
| LHIU/L | 2.1 | 4.4 | +110% | Optimal | |
| FSHIU/L | 2.4 | 3.6 | +50% | Optimal | |
| Estradiol (sensitive)pg/mL | 14 | 26 | +86% | Optimal | |
| Testosterone : estradiol ratioratio | 29.4 | 30.1 | +2% | Optimal | |
| DHEA-Sµg/dL | 188 | 372 | +98% | Optimal | |
| Prolactinng/mL | 13.8 | 8.1 | −41% | Optimal | |
| Progesteroneng/mL | 0.14 | 0.31 | +121% | Optimal | |
| PSA, totalng/mL | 0.8 | 0.9 | +12% | Optimal |
Longevity - atherogenic burden
Cardiovascular risk
| Marker | Baseline | Follow-up | Change | Trend | Status |
|---|---|---|---|---|---|
| ApoBmg/dL | 118 | 71 | −40% | In range | |
| Lp(a)nmol/L | 46 | 44 | −4% | Optimal | |
| LDL particle numbernmol/L | 1486 | 940 | −37% | Optimal | |
| LDL cholesterolmg/dL | 142 | 84 | −41% | In range | |
| HDL cholesterolmg/dL | 42 | 58 | +38% | Optimal | |
| Triglyceridesmg/dL | 186 | 74 | −60% | Optimal | |
| Triglyceride : HDL ratioratio | 4.4 | 1.3 | −70% | Optimal | |
| Remnant cholesterolmg/dL | 34 | 13 | −62% | Optimal | |
| Omega-3 index% | 4.2 | 8.9 | +112% | Optimal |
Longevity - glycaemic control
Metabolic & inflammatory
| Marker | Baseline | Follow-up | Change | Trend | Status |
|---|---|---|---|---|---|
| Fasting insulinµIU/mL | 14.2 | 4.6 | −68% | Optimal | |
| HOMA-IRindex | 3.4 | 1 | −71% | Optimal | |
| Fasting glucosemg/dL | 98 | 86 | −12% | Optimal | |
| HbA1c% | 5.6 | 5.1 | −9% | Optimal | |
| hs-CRPmg/L | 2.8 | 0.5 | −82% | Optimal | |
| Homocysteineµmol/L | 12.4 | 7.6 | −39% | Optimal | |
| Uric acidmg/dL | 6.9 | 5.2 | −25% | Optimal | |
| IGF-1ng/mL | 96 | 148 | +54% | Optimal | |
| Leptinng/mL | 11.8 | 4.1 | −65% | Optimal |
Systems - capacity and clearance
Organ function & thyroid
| Marker | Baseline | Follow-up | Change | Trend | Status |
|---|---|---|---|---|---|
| ALTU/L | 44 | 22 | −50% | Optimal | |
| ASTU/L | 34 | 24 | −29% | Optimal | |
| GGTU/L | 41 | 18 | −56% | Optimal | |
| eGFRmL/min/1.73 | 88 | 98 | +11% | Optimal | |
| Cystatin Cmg/L | 0.94 | 0.78 | −17% | Optimal | |
| Albumin : creatinine ratiomg/g | 14 | 6 | −57% | Optimal | |
| TSHmIU/L | 3.2 | 1.6 | −50% | Optimal | |
| Free T3pg/mL | 2.6 | 3.5 | +35% | Optimal | |
| Free T4ng/dL | 1 | 1.3 | +30% | Optimal | |
| Reverse T3ng/dL | 22 | 13 | −41% | Optimal |
Foundations - substrate availability
Micronutrients & blood
| Marker | Baseline | Follow-up | Change | Trend | Status |
|---|---|---|---|---|---|
| Vitamin D, 25-OHng/mL | 22 | 62 | +182% | Optimal | |
| Vitamin B12pg/mL | 318 | 664 | +109% | Optimal | |
| Folate, serumng/mL | 6.1 | 14.2 | +133% | Optimal | |
| Magnesium, RBCmg/dL | 4.4 | 5.9 | +34% | Optimal | |
| Zinc, plasmaµg/dL | 71 | 104 | +46% | Optimal | |
| Ferritinng/mL | 214 | 118 | −45% | Optimal | |
| Transferrin saturation% | 47 | 33 | −30% | Optimal | |
| Haemoglobing/dL | 14.6 | 15.4 | +5% | Optimal | |
| Haematocrit% | 43.1 | 46.2 | +7% | Optimal | |
| White cell countK/µL | 7.9 | 5.6 | −29% | Optimal | |
| PlateletsK/µL | 289 | 264 | −9% | Optimal |
Physical & performance
Assessment deltas
VO2max
mL/kg/min
Resting heart rate
bpm
HRV (rMSSD)
ms
Heart rate recovery, 1 min
bpm drop
Systolic blood pressure
mmHg
Diastolic blood pressure
mmHg
Body weight
kg
Body fat
%
Lean mass
kg
Visceral adipose tissue
cm²
Waist : height ratio
ratio
Bone mineral density (T-score)
SD
Grip strength (dominant)
kg
Trap-bar deadlift 3RM
kg
Weighted carry
m at 2 × 32 kg
Dead hang
seconds
Overhead mobility screen
score /10
Single-leg balance, eyes closed
seconds
Gait speed
m/s
Total sleep time
hours
Deep sleep
minutes
Sleep efficiency
%
Nocturnal respiratory events
per hour
Your next phase
Your follow-up shows which parts of the protocol produced a measurable response and where the next 90 days should focus. Your next full panel and assessment are already scheduled.